At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib, DA-EPOCH-R, and 1 other intervention for Diffuse Large B Cell Lymphoma Relapsed and Diffuse Large B Cell Lymphoma Refractory. Completed, enrolled 35 participants across 10 sites.
Detailed Summary
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionAug 2017
TodayJul 2026
First PostedMay 20, 2014
Enrollment StartMay 1, 2014
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.1 years ago
Interventions
Ibrutinibdrug
Ibrutinib
DA-EPOCH-Rdrug
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
Lenalidomidedrug
Lenalidomide